{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056291","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.139574+00:00","generated_at":"2026-06-02T06:02:54.316608+00:00","sec_items":["8.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Corbus updates risk factors; no new operational or financial events","bullets":["Filing supplements risk factors for Q1 2024; no change in business outlook.","Highlights dependence on contract manufacturers and CROs for clinical supply.","Notes exposure to U.S.-China trade policies and proposed BIOSECURE bill through CSPC license.","Repeats standard IP infringement litigation risks; no suits filed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056291","json":"https://secwatch.observer/filing/0000950170-24-056291.json","markdown":"https://secwatch.observer/filing/0000950170-24-056291.md","text":"https://secwatch.observer/filing/0000950170-24-056291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024056291/0000950170-24-056291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024056291/crbp-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:02:54.316608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}